Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have received a consensus rating of “Moderate Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $8.50.

PGEN has been the subject of several research reports. Wall Street Zen downgraded shares of Precigen from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Wednesday, October 8th. Finally, HC Wainwright boosted their price target on shares of Precigen from $8.50 to $9.00 and gave the company a “buy” rating in a research report on Friday, November 14th.

Precigen Trading Down 0.5%

Shares of NASDAQ PGEN opened at $4.39 on Friday. Precigen has a twelve month low of $1.11 and a twelve month high of $5.22. The company has a current ratio of 4.04, a quick ratio of 3.95 and a debt-to-equity ratio of 2.22. The stock has a fifty day simple moving average of $4.09 and a 200-day simple moving average of $3.50. The stock has a market capitalization of $1.55 billion, a PE ratio of -3.16 and a beta of 1.10.

Precigen (NASDAQ:PGEN) last posted its earnings results on Thursday, November 13th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The firm had revenue of $2.92 million for the quarter, compared to analyst estimates of $0.67 million. Precigen had a positive return on equity of 1,066.10% and a negative net margin of 3,912.92%. On average, equities analysts forecast that Precigen will post -0.32 earnings per share for the current year.

Insider Activity at Precigen

In other news, Director Randal J. Kirk sold 1,900,036 shares of the stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $4.18, for a total transaction of $7,942,150.48. Following the completion of the sale, the director owned 341,189 shares in the company, valued at approximately $1,426,170.02. This represents a 84.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 4,866,329 shares of company stock valued at $20,233,899 over the last three months. 47.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of PGEN. Caitong International Asset Management Co. Ltd purchased a new position in Precigen during the 3rd quarter worth $39,000. Russell Investments Group Ltd. acquired a new stake in shares of Precigen in the third quarter valued at about $41,000. Asempa Wealth Advisors purchased a new position in Precigen in the 4th quarter valued at approximately $48,000. Vontobel Holding Ltd. acquired a new stake in Precigen in the third quarter valued at $48,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in Precigen in the third quarter valued at $53,000. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.